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mRNA for N-Bak, a neuron-specific BH3-only splice
isoform of Bak, escapes nonsense-mediated decay
and is translationally repressed in the neurons
M Jakobson1, A Lintulahti1,2 and U Aruma¨e*,1
mRNA for neuronal Bak (N-Bak), a splice variant of pro-apoptotic Bcl-2 family member Bak is expressed in the neurons.
Surprisingly the endogeneous N-Bak protein cannot be demonstrated in the neurons, although the antibodies recognize N-Bak
protein from in vitro translation or transiently transfected cells. As N-Bak mRNA contains premature termination codon (PTC) at
89 nucleotides upstream from the last exon–exon junction, it could be degraded by nonsense-mediated decay (NMD) during the
pioneer round of translation thus explaining the absence of the protein. We show here that the endogeneous neuronal N-Bak
mRNA is not the NMD substrate, as it is not accumulating by cycloheximide treatment, it has a long lifetime, and even prevention
of PTC by interfering with the alternative splicing did not lead to translation of the Bak mRNA. N-Bak protein is also not revealed
by proteasome inhibitors. Our data suggest strong translational arrest of N-Bak mRNA in the neurons. We show that this arrest is
partially mediated by 50-untranslated region of Bak mRNA and it is not released during mitochondrial apoptosis.
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Nonsense-mediated mRNA decay (NMD) is a cellular
surveillance mechanism to recognize and degrade mRNAs
harboring premature translation-termination codon (PTC).
Truncated proteins encoded by such mRNAs could be
deleterious for the cell. During pioneer round of translation,
the cell carries out quality control of the mRNA and either
passes it to produce the proteins or directs it to the NMD-
mediated degradation.1,2 Specific multiprotein exon junction
complexes deposited on the exon–exon junctions during pre-
mRNA splicing are detected and removed by the ribosome
during pioneer round of translation. In mammals, one of the
main criteria for the NMD substrate mRNAs is that distance of
the PTC to the last (i.e. the 30-most) exon–exon junction must
be longer than 55 nucleotides (55-nt NMD rule).3 If so, this last
exon junction complex is recognized as a signal for NMD and
the mRNA is degraded.2 Classically, the NMD is considered
as a mechanism to remove aberrant mRNAs where PTC is
generated bymutations. Many PTCs, however, are generated
by physiological alternative splicing, where inclusion or
exclusion of a cassette exon causes translational frameshift.
About one-third of the alternatively spliced mRNAs is
estimated to include isoforms with PTC that meet the 55-nt
NMD rule and could potentially be degraded by NMD.4,5
To what extent such PTCs, generated by natural splicing
process, actually trigger NMD is not clear.
We have described a splice variant of pro-apoptotic BH1-3-
domain Bcl-2 family member Bak that we named N-Bak for
‘neuronal Bak’ because it is expressed only in the neurons and
not in any other tested primary cells or tissues,6 as also
reported by others.7 N-Bak is generated by inclusion of a
20 nucleotide cassette exon (exon N for ‘neuronal’) that causes
a translational frameshift and PTC, such that instead of a BH1-3
Bak, a typical BH3-only protein N-Bak is encoded.6,8 The
neurons splice Bak pre-mRNA completely into N-Bak tran-
scripts such that the neurons specifically do not express Bak
at all.6,8 Surprisingly we6 and others9 were not able to detect
N-Bak protein in the neurons (although Uo et al.8 reported the
protein by immunoblot). The PTC on the N-BakmRNA locates
at 89 nucleotides upstream from the last exon–exon junction
(Figure 1c) corresponding to the 55-nt NMD rule. Thus, the
N-Bak mRNA could be degraded during the pioneer round of
translation, explaining the absence of the protein.
In this study we set up to test the hypothesis that N-Bak
mRNA is degraded in the neurons by NMD that causes
absence of the protein. Our results suggest that N-Bak mRNA
is not the NMD substrate in the neurons and thus belongs to
the mRNAs that escape the NMD despite the correspondence
to the 55-nt NMD rule. Our data suggest that N-Bak mRNA is
translationally arrested and its 50-untranslated region (UTR) is
partially responsible for this arrest.
Results
N-Bak mRNA but not protein is expressed in the
neurons. Earlier we6 and others9 were not able to detect
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N-Bak protein in the neurons. To study the issue further,
we tested four anti-Bak antibodies: 06-536 (EMD Millipore/
Upstate, Darmstat, Germany), B-5897 (Sigma, St. Louis, MO,
USA), Ab-2 (EMD Millipore/Calbiochem, Darmstat, Germany)
and G-23 (Santa Cruz, sc-832, Heidelberg, Germany). First
two antibodies are raised against the peptides from the
N-terminal region common for both Bak and N-Bak, whereas
the epitopes for two latter antibodies are not precisely
defined.
We first tested the antibodies on the in vitro translated
N-Bak and Bak and on the HeLa cells transiently transfected
with the respective expression plasmids. Two antibodies
(Sigma B-5897 and EMD Millipore 06-536) against the
N-terminal region of Bak/N-Bak recognized both about
25 kD Bak and about 20 kD N-Bak in either approach
(Supplementary Figure 1) and these antibodies were used
in the subsequent experiments. Other two antibodies (Ab-2
and G-23) did not show specific binding (data not shown).
Antibody Ab-2 has been used8 to demonstrate N-Bak protein
in the cortical neurons. Why it did not work in our hands is not
clear. Immunostaining of the cultured neurons with any
of the four anti-Bak antibodies results in high non-specific
background (data not shown). Thus, at least two antibodies
specifically detected N-Bak protein when it is expressed from
the plasmid.
We then compared the levels of transcripts and proteins of
Bak isoforms in the mouse brain. The cultured cells used in
this study were analyzed as well. Transcripts for Bak isoforms
were detected by RT-PCR with primers flanking exon N6
(Figure 1c), thus amplifying both mRNAs with comparable
efficiency. As shown on Figure 1a, in the newborn (P0) mouse
brain the level of N-Bak transcripts (from the neurons) is highly
surpassing the level of BH1-3 Bak transcripts (from the non-
neuronal cells) that is in agreement with the results of RNase
protection assay.6 N-Bak transcripts were easily detected in
the cultures of cortical and sympathetic neurons; the low
levels of Bak transcripts in these cultures result from the few
contaminating non-neuronal cells.6 Rat pheochromocytoma
PC6 cells express exceptionally the mRNAs for both Bak
isoforms, the levels of N-Bak mRNA being very low. As
expected, only Bak but not N-Bak transcripts were detected in
the P0 mouse liver tissue and NIH-3T3 mouse fibroblast cells.
The proteins were analyzed from the other half of the same
samples by immunoblot. In agreement with previous study6
the anti-Bak antibody (EMD Millipore) did not detect N-Bak
protein in any of the tissues or cells whereas the Bak protein
was always detected (Figure 1b). The same results were
obtained with antibody from Sigma, whereas other two
antibodies gave again poor results (data not shown).
Thus, despite the high levels of N-Bak mRNA the protein
was not detected in the neurons, although our assay easily
revealed Bak protein from the samples with significantly lower
Bak mRNA levels. We conclude that the absence of N-Bak
protein in the neurons results from the posttranscriptional
regulation rather than minute amounts of the mRNA. We
considered three mechanisms that could lead to the absence
of N-Bak protein: (i) rapid degradation of the mRNA, (ii) rapid
degradation of the protein and (iii) translational block of
the mRNA.
N-Bak mRNA is not the substrate for NMD. Inclusion of
exon N to the Bak mRNA generates PTC that corresponds to
the 55-nt NMD rule (Figure 1c). Such mRNA could potentially
be degraded during the pioneer round of translation thus
explaining the absence of N-Bak protein. To test this
hypothesis we blocked translation by cycloheximide (CHX)
that should lead to rapid accumulation of the NMD substrate
mRNAs.10,11 We treated cultured cortical neurons with CHX
for 4 and 8h and determined the levels of N-Bak transcripts
by quantitative RT-PCR (qRT-PCR). mRNA for Bax, another
pro-apoptotic Bcl-2 family member that does not contain
PTC was also analyzed for comparison. The data were
normalized to two reference mRNAs – neurofilament, medium
polypeptide (NEFM) and enolase 2 (ENO2) that, just as N-
Bak, are specifically expressed in the neurons but not in the
small number of non-neuronal cells that are always present
in the cultures. The fold changes were calculated in relation
to samples treated with vehicle (DMSO) using relative
expression software tool REST.12 As shown in Table 1,
blockage of translation for 4 h did not lead to accumulation of
N-Bak or Bax transcripts in the cortical neurons, whereas
Figure 1 Expression of transcripts and proteins of Bak isoforms in the newborn
(P0) mouse tissues, cultured mouse neurons, mouse NIH3T3 fibroblasts and
rat pheochromocytoma PC6 cells. (a) RT-PCR detection of the transcripts of Bak
(510 nt) and N-Bak (530 nt). (b) Immunoblot from the other half of the same samples
probed with anti-Bak antibodies (06-536, EMD Millipore). The positions of about
20 kD N-Bak and about 25 kD Bak proteins are shown on the lanes of HeLa cells
overexpressing the respective apoptotically inactive L76E mutants. Note the
absence of endogeneous N-Bak in all lanes. Pure glial cells from the P0 mouse
cortex also expressed Bak but not N-Bak. Low levels of Bak in the cortical and
sympathetic cultures come from the contaminating non-neuronal cells. Longer
exposition of the filter still did not reveal N-Bak protein (not shown). (c) Schematic
cartoon of the fragment of N-Bak mRNA showing start codon (SC), exon N (N), PTC
and the authentic translation termination codon (TC). The exon–exon junctions are
shown by vertical bars. Localization of the primers for PCR is shown by arrows
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small but significant accumulation of N-Bak but not Bax
occurs by 8 h of CHX treatment. However, this increase was
completely blocked by transcription inhibitor actinomycin D
(ActD). Thus, this late and small increase in the N-Bak
mRNA was caused by increased transcription, most probably
because of CHX-induced cellular stress.13 The same results
were obtained with another pair of N-Bak-specific primers
(mouse N-Bak-2, data not shown), or when data were
calculated in relation to untreated samples instead of DMSO-
treated samples (data not shown). In the PC6 cells, similar
CHX-induced increase in the N-Bak mRNA level (normalized
to beta actin) was observed by 4h of treatment but was
also completely blocked by co-treatment with ActD (data not
shown).
As a rule, the NMD substrate mRNA levels are low because
of ongoing degradation.14,15 If N-Bak mRNA were a substrate
for NMD in the neurons, its turnover should be extremely
rapid, as the levels of this transcript in the brain and cultured
neurons are high (Figure 1). To study the stability of N-Bak
mRNA we blocked transcription in the cortical cultures by
ActD and determined the time-dependency of N-Bak and Bax
mRNA degradation by qRT-PCR. The data were normalized
to 7SL RNA (RN7SL1) and 18s ribosomal RNA (Rn18s) that
are transcribed by RNA polymerase III and thus not blocked
by ActD. As shown on Figure 2, the N-Bak transcripts were
stabile in the cortical neurons, whereas the levels of Bax
transcripts decreased in time (Figure 2b). Longer treatments
with ActD caused general deterioration of the cortical cultures
that makes the analysis unreliable. Similar results were
obtained using another pair of N-Bak-specific primers (mouse
N-Bak-2, data not shown). In the ActD-treated PC6 cells, the
transcripts of N-Bak decreased with the same rate as the
transcripts of Bax (data not shown).
In summary, the N-Bak mRNA is remarkably stabile in the
neurons. Such stability is not compatible with theNMDsubstrate
transcripts. Thus, our data do not support the hypothesis that
N-Bak mRNA is degraded in the neurons by NMD.
Prevention of alternative splicing and PTC did not lead
to translation of N-Bak mRNA. The experiments with CHX
and ActD treatment described above suggest that despite of
the PTC falling under the 55-nt NMD rule, N-Bak mRNA is
not the NMD substrate in the neurons. To study the issue
further we tested whether this mRNA could be translated
without PTC. To that end we designed Vivo-Morpholino
oligonucleotides against exon N that should prevent its
inclusion into the endogeneous mRNA. Without exon N the
mRNA has no PTC and encodes for the BH1-3 Bak in the
neurons. Application of the exon N-specific oligonucleotides
to the culture medium of cortical neurons for 24 h indeed
leads to significant appearance of Bak mRNA with conco-
mitant disappearance of N-Bak mRNA, whereas control
oligonucleotides had no effect (Figure 3a). However,
immunoblot with anti-Bak antibody (06-536, EMD Millipore)
did not reveal upregulation of Bak protein in such cortical
cultures forced to express Bak mRNA (Figure 3b). Addition of
Table 1 Relative changes of N-Bak and Bax transcripts in the cortical neurons treated with CHX or co-treated with cycloheximide (CHX) and actimomycin D (ActD) as
determined by qRT-PCR and analyzed by relative expression software tool REST
Transcript Type Reaction
efficiency
Expression S.E. 95% CI P(H1) Result
4h CHX (n¼3)
Eno2 REF 0.9019 0.934
NEFM REF 0.8904 1.071
N-Bak TRT 0.8881 1.880 1.149–3.586 0.828–4.237 0.209
Bax TRT 0.81 0.825 0.481–1.511 0.341–2.241 0.713
8h CHX (n¼4)
Eno2 REF 0.9019 0.981
NEFM REF 0.8904 1.020
N-Bak TRT 0.8881 2.890 2.229–3.846 1.755–4.346 0.020 UP
Bax TRT 0.81 1.076 0.599–1.720 0.425–2.681 0.821
8h CHX+ActD (n¼ 4)
Eno2 REF 0.8876 0.954
NEFM REF 0.8904 1.048
N-Bak TRT 0.9314 1.154 0.896–1.487 0.768–1.806 0.336
Bax TRT 0.9589 1.046 0.508–2.055 0.309–3.708 0.891
Abbreviations: ENO2, enolase 2; NEFM, neurofilament, medium polypeptide. The data of the target transcripts (TRT) are normalized to the indicated reference
transcripts (REF). The sample groups (CHX or CHX+ActD) are compared with control groups (DMSO). P(H1) designates the probability of alternate hypothesis that
difference between sample and control groups is due only to chance n designates the number of independent repeat experiments
Figure 2 Stability of N-Bak mRNA. Cortical neurons were treated with the
transcription inhibitor ActD (5 mg/ml) and analyzed by qRT-PCR at indicated time
points. The levels of N-Bak and Bax transcripts were normalized to 7SL RNA
(RN7SL1) and Rn18s. Each time point was calculated in relation to untreated
samples by relative expression software tool REST. The trendlines are shown by
black lines. The data are results of three independent experiments
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caspase inhibitor BAF or proteasome inhibitor MG-132 to the
culture medium still did not lead to increase in the Bak protein
levels in the oligonucleotide-treated cultures (data not
shown). Thus, despite the absence of exon N and PTC the
endogenous Bak mRNA was not translated in the neurons.
The data suggest that a translational arrest rather than NMD
causes the absence of N-Bak protein.
N-Bak protein is not rapidly degraded by
proteasome. One explanation for the absence of N-Bak
protein could be its rapid proteasomal degradation. In
support of this possibility, the Mobyle program predicted
a PEST sequence (signal for proteasome-mediated
degradation) encompassing residues 12–33 of mouse Bak/
N-Bak. To address this alternative we treated the cortical
neurons with proteasome inhibitor MG-132 in the presence
or absence of caspase inhibitor BAF. N-Bak protein was not
detectable in these conditions whereas control heat shock
protein (Hsp70) was strongly upregulated by proteasome
inhibition (Figure 4), as published.16 Thus we did not find
evidences for rapid proteasome-mediated degradation of
N-Bak protein. Moreover, the BH1-3 Bak protein is easily
detected in many cells and tissues despite the presence of
this predicted PEST sequence.
N-Bak protein was not induced in the apoptotic
neurons. As a typical BH3-only protein, N-Bak could
function in the Bax-dependent mitochondrial apoptosis. If
so, the translational arrest could be released and N-Bak
protein expressed in the apoptotic neurons. We treated the
cortical neurons with etoposide, the inhibitor of topomerase II
that triggers mitochondrial apoptosis, for 24–36 h. The death
of the neurons was blocked by caspase inhibitor BAF with or
without proteasome inhibitor. Immunoblot with anti-Bak
antibodies (06-536, EMD Millipore) (Figure 5) or Sigma
(data not shown) again did not show appearance of N-Bak
protein in any of these conditions. The same result was
obtained when the sympathetic neurons were deprived of
nerve growth factor, or treated with etoposide for three days
in the presence of BAF (data not shown). Thus, N-Bak
mRNA is not translated during the mitochondrial apoptosis,
at least not at the detectable level. The membranes were
reprobed with antibody Ab-2 used by others to demonstrate
N-Bak in the camptothecin-treated cortical cultures8 but no
specific binding was detected (data not shown).
Translational arrest of N-Bak mRNA is partially mediated
by 50-UTR. To study the mechanism of translational arrest of
N-Bak mRNA we focused on its 50-UTR that contains two
open reading frames upstream of the translation initiation
codon. Such 50-UTRs can participate in the translational
repression of mRNAs.17,18 We tested the effect of Bak
50-UTR on the translation using Dual Luciferase Reporter
assay with Firefly and Renilla luciferase (FF-Luc and Rn-Luc,
respectively). The 50-UTR of mouse Bak mRNA was cloned
upstream of the Firefly luciferase reporter gene, resulting in a
Bak-50-UTR-FF-Luc construct, whereas the reporter without
the Bak 50-UTR (FF-Luc) was used for a reference.
Figure 3 Bak mRNA is not translated in the absence of PTC. (a) RT-PCR
analysis of the transcripts of Bak (510 nt) and N-Bak (530 nt) in the cultured cortical
neurons treated with exon N-targeting or control Vivo-Morpholino oligonucleotides
at 4 or 8 mg/ml for 24 h. N-Bak mRNA is converted into Bak mRNA with exon
N-specific (target oligos) but not control oligos. Qualitatively same results were
obtained in three independent experiments. (b) Upper panel: immunoblot with
Bak-specific antibodies (06-536, EMD Millipore) from the other half of the same
samples as in (a). The position of about 25-kD Bak is shown on the lane of HeLa
cells overexpressing Bak-L76E. The Bak on the neuronal lanes comes from the
contaminating glial cells and its level is not increased by the oligonucleotide
treatment. Lower panel: reprobing the same filter with antibodies to b-actin.
Qualitatively same results were obtained in three independent experiments
Figure 4 N-Bak protein is not revealed by proteasome inhibition. Cortical
neurons were treated with proteasome inhibitor MG-132 for 16 or 24 h in the
presence or absence of caspase inhibitor BAF, or with the vehicle (DMSO). Upper
panel shows the immunoblot with anti-Bak antibodies (06-536, EMD Millipore).
Shown are the samples from HeLa cells transiently transfected with the inactive
L76E mutants of Bak and N-Bak. Lower panel shows the same filter reprobed with
anti-Hsp70 antibodies. Proteasome inhibition did not reveal N-Bak protein in
the cortical neurons, although the positive control Hsp70 was strongly induced. The
HeLa cells express Hsp70 constitutively. The same results were obtained in three
independent experiments
Figure 5 N-Bak protein is not induced in the apoptotic neurons. Cortical
neurons were treated with etoposide for 24 or 36 h in the presence of proteasome
inhibitor MG-132 or caspase inhibitor BAF. Untreated and vehicle (DMSO)-treated
cultures as well as HeLa cells overexpressing apoptotically inactive L76E mutants of
N-Bak and Bak were included as controls. The immunoblot is probed with anti-Bak
antibody (06-536, EMD Millipore). The same results were obtained in three
independent experiments
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Sympathetic neurons were microinjected with the plasmid
mixtures of either Bak-50-UTR-FF-Luc/Rn-Luc or FF-Luc/
Rn-Luc. Relative luciferase activity was determined 48h later
by normalization of FF-Luc activity to Rn-Luc activity. The
activity of luciferase in the Bak-50-UTR-FF-Luc-injected
neurons constituted 37.6±3.6% (S.E.M., n¼ 3) of that in
the FF-Luc-injected neurons after 48 h. Thus, the presence of
Bak 50-UTR in front of the FF-Luc gene strongly reduced its
activity.
Discussion
The main aim of this study was to address whether the N-Bak
mRNA is the substrate for NMD that could explain the
absence of the encoded protein in the neurons. Inclusion of a
20-nucleotide exon N to N-Bak mRNA causes a translational
frameshift and PTC that corresponds to the 55-nt rule of NMD.
Such mRNAs should be degraded in the pioneer round of
translation and could therefore not produce significant amount
of the protein.
The main finding of this study is that N-Bak mRNA is not the
substrate for NMD in the neurons. The evidences for this
conclusion are the following. (i) Blockage of translation with
CHX did not lead to rapid and massive accumulation of N-Bak
mRNA in the cortical neurons. (ii) mRNA for N-Bak was
remarkably stable in the neurons that is not compatible with
translation-associated rapid degradation. (iii) Abrogation of
PTC from the neuronal N-Bak mRNA did not lead to its
translation. We conclude that neurons have specific mechan-
ism(s) to avoid NMD of the N-Bak mRNA, possibly via
translational repression. Of note, we studied here the
endogenous PTC-containing transcripts in their natural
neuronal environment instead of tumor cell lines transfected
with artificial plasmid constructs that might not be subjected
to all cellular regulations. On the other hand, blockage of
endogeneous NMD by siRNAs to Upf1/RENT15 that is a
common approach to identify NMD substrates appeared
technically too complicated in the primary neurons.
Endogeneous N-Bak protein has been detected by others
by antibody Ab-2.8 We put special efforts to repeat these
results but in our hands the antibody was not specific, even in
the HeLa cells transfected with inactive Bak. The reason for
this discrepancy is not clear and formally it cannot be excluded
that we have not found the proper conditions for N-Bak
immunoblot. However, different biochemical approaches
including various solubilization buffers, immunoprecipitations
and so on never revealed endogenous N-Bak protein with any
anti-Bak antibody tested, although plasmid-expressed N-Bak
was always seen.6
Classically, the NMD has been described for mRNAs where
the PTC is generated by aberrations. However, it is estimated
that about one-third of alternatively spliced mRNAs have
PTC-containing isoform(s) that could potentially be degraded
by NMD.4,5 Such physiological generation of PTC could be a
mechanism to regulate gene expression, a process termed
regulated unproductive splicing and translation (RUST).19
Although the issue is not clear, some studies estimated that
only up to 10% of such transcripts accumulate when NMD is
blocked15,20,21 showing that a considerable portion can
escape the NMD. Our data suggest that N-Bak mRNA is not
the typical case of RUST, where the alternative splicing-
generated PTC is exploited to downregulate the mRNA.22–24
Instead, the mRNA appears to be maintained in a transla-
tionally repressed state independently (and despite) of the
PTC (Figure 3). N-Bak mRNA thus belongs to the class of
NMD-escape mRNAs which are translationally repressed.25
The mechanisms of translational arrest and the strong
stability of N-Bak mRNA remain to be studied. Our results
show that the 50-UTR of Bak mRNA strongly reduces the
translation of the reporter gene in the neurons, suggesting that
it participates in the translational repression of N-Bak mRNA.
50-UTR of mouse, rat and human Bak contain short open
reading frames upstream of the translation initiation site
shown to be essential in the translational repression of the
mRNAs.17,18 However, the 50UTR of Bak did not repress
expression of the reporter gene completely, suggesting the
participation of other mechanism as well. The potential
candidates are the microRNAs known to repress mRNA
translation via 30-UTR.26–29
The splicing of Bak pre-mRNA (inclusion of exon N) is
triggered around the time the neuronal progenitors exit the cell
cycle (our unpublished data). Moreover, the sequence,
regulatory elements (branch point and poly-pyrimidine tract)
and the position of exon N between constitutive exons 4 and 5
of the Bak gene are evolutionally conserved. Thus, the
absence of Bak (and presence of N-Bak mRNA) is a pan-
neuronal feature that seems to last throughout the lifetime of
the neurons. It is tempting to speculate that the biological
meaning of neuronal Bak pre-mRNA splicing is to get rid of an
apoptotic effector Bak. Indeed, the death machinery is under
stringent brakes in the postmitotic neurons, such as blockage
of Bax protein,30 strong association of the caspases
with XIAP protein,31–33 low levels of Apaf-1 (Wright et al.34,
Wright et al.35 ) and so on. Removal of Bak by alternative
splicing could be one additional brake to make the neurons
more resistant to accidental apoptosis. The biological mean-
ing of N-Bak mRNA remains currently unclear. Exon N is
inserted to the Bak pre-mRNAwith exact precision (just before
the BH1 domain-encoding sequence) that converts the BH1-
3-type protein into the BH3-only protein. Thus, the neurons
seem to require an additional member to their repertoire of
BH3-only proteins and generate it by alternative splicing of
Bak. Curiously, the N-Bak mRNA is stabilized and transla-
tionally repressed in the neurons, and this repression is not
relieved in the classical apoptotic situations (this study) or in
many other stress conditions (our unpublished data). When (if
ever) this mRNA is translated remains currently unknown.
Materials and Methods
Cell cultures. The cortical neurons from the embryonic day 15–16 mice,
dissociated as published,6 were grown on the polyornithine-coated 35-mm plastic
dishes (Becton Dickinson, Franklin Lakes, NJ, USA) in the Neurobasal medium
(Invitrogen, Carlsbad, CA, USA) containing 2% of B27 serum supplement
(Invitrogen), 0.5mM L-Glutamine and 100mg/ml Primocin (InvivoGen, San Diego,
CA, USA) for 5–6 days before the experiments. The cultures containing many non-
neuronal cells were excluded, although completely glia-free cultures were not
possible. The experiments were repeated on the independent cultures 3–5 times.
The newborn mouse sympathetic neurons were cultured on the dishes coated
with polyornithine-laminin (Sigma) in the Neurobasal medium containing B27
supplement (Invitrogen) and 30 ng/ml mouse 2.5 S NGF (Promega, Madison, WI,
USA), as published.36,37 PC6 cells were grown in DMEM (Invitrogen) containing
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10% of horse serum (PAA Laboratories, Pasching, Austria), 5% of fetal bovine
serum (HyClone, Thermo Scientific, Loughborough, UK) and 100 mg/ml of Normocin
(InvivoGen); HeLa, primary glia and NIH-3T3 cells were grown in DMEM (Invitrogen)
containing 10% fetal bovine serum (HyClone) and 100mg/ml Normocin. The
following additives were used: CHX (Sigma) in DMSO at 20 mg/ml, ActD (Sigma)
at 5mg/ml, proteasome inhibitor MG-132 (Sigma) at 10 mg/ml, pan-caspase
inhibitor boc-aspartyl(OMe)-fluoromethylketone (BAF) (Calbiochem/EMD Bio-
sciences, Darmstadt, Germany) at 25 mg/ml, etoposide (Sigma) at 4 mg/ml. The
cell membrane-penetrating Vivo-Morpholino oligonucleotides (GeneTools, LLC,
Philomath, OR, USA) were designed against the region encompassing exon N
(50-ACCTGTGCATGTTGCTGCTGGCCT-30), control sequence (50-AGCGCACGA
TCAACATGCAGACGG-30) and applied to the culture medium at 4 or 8mg/ml for
8 or 24 h.
Primers. PCR primers were designed using Primer Express v2.0. software
(Applied Biosystems, Carlsbad, CA, USA) or OligoAnalyzer software (eu.idtdna.com)
and ordered from Sigma. PCR primers:
N-Bak/Bak F: 50-TTGCCCAGGACACAGAGGAGGT-30, N-Bak/Bak R: 50-GAA
TTGGCCCAACAGAACCACACC-30.6 mBak 50-UTR F: 50-GATTAAGCTTGGAGCT
GGGACCTCCTCTATG-30, mBak 50-UTR R: 50-ACTTAA GCTTGAATTCACCACC
GTCACTTGTCAC-30.
Quantitative PCR primers: mouse 7SL ncRNA F: 50-CGATCGGGTGTCC
GCACTAAGT-30 R: 50-TGGTCGTTCACCCCTCCTTAGG-30, rat 7SL ncRNA F:
50-GTTTCCGACCTGCGCCGGTTC-30 R: 50-TATGCCGATCGGGTGTCCGCAC-30,
Rn18s F: 50-GCACGGCCGGTACAGTGAAACT-30, R: 50-AGCGCCCGTCGGCAT
GTATTAG-30, mouse N-Bak 1 F: 50-TGCTGATGGCAACTTCAACTG-30 R: 50-AG
CCAAAGCCCAGGAGAG-30, mouse N-Bak 2 F: 50-CAGCAACATGCACAGCCT
AT-30 R: 50-CTGTGCATGTTGCTGCTGG-30, Bax F: 50-TTGCTGATCTTGTCGT
CGGACTGT-30 R: 50-CAGCCCATGATGGTTCTGATC-30, ENO2 F: 50-CTGCAGT
CCAAGAGCATCGA-30 R: 50-ATGAGCTGGTTGTACTTCGCCAGA-30, NEF-M F:
50-GCTACGACACGGAGTTCCAGA-30 R: 50-ACTGCTGGATGGTGTCCTGG-30,
rat N-Bak F: 50-ATGGAATCCTGTGGCATCCAT-30 R: 50-GTGCATGCCGCTGCT
GCTG-30, Actb F: 50-ATGGAATCCTGTGGCATCCAT-30 R: 50-CCACCAGACAAC
ACTGTGTTGG-30.
Cloning. Mouse BAK1 50-UTR fragment (bp -247-19) was amplified by PCR
from the whole E10.5. embryo cDNA using primers mBak 50-UTR F and mBak
50-UTR R. Purified PCR product was inserted into the HindIII site of pGL4.13 vector
(Promega) resulting in Bak-50-UTR-FF-Luc-pGL4.13 construct, named Bak-50-UTR-
FF-Luc. The expression plasmids for N-Bak, Bak, N-Bak-L76E and Bcl-xL are
published.6,36,38
Microinjections and luciferase assay. Microinjection of the neurons was
performed essentially as published.6,36 Briefly, the neurons were grown with NGF
for 5–6 days and pressure-microinjected with the expression plasmids: either
Bak-50-UTR-FF-Luc-pGL4.13 or FF-Luc-pGL4.13 (10 ng/ml), both mixed with
Rn-Luc-pGL4.73 (5 ng/ml). In all 200–300 neurons were injected per experimental
point. Forty-eight hours later the neurons were lysed in the Passive Lysis Buffer and
the luciferase activities determined using Dual-Luciferase Reporter Assay System
(Promega) and GloMax 20/20 luminometer (Promega) according to the
manufacturer’s instructions. The experiments were repeated three times on
independent cultures.
RT-PCR. Total RNA was extracted from the P0 mouse brain and liver, from
whole mouse embryos (E10.5) or from cultured cells by TRI-reagent (Molecular
Research Center, Cincinnati, OH, USA) according to the manufacturer’s
instructions. Isolated RNA was dissolved in the RNase-free water and treated
with DNAse I and removal reagents from TURBO DNA-free kit (Ambion, Austin, TX,
USA). Total RNA concentrations and absorbance ratios were measured
by NanoDrop spectrophotometer. In all, 2 mg of isolated RNA was used for
cDNA synthesis in the 20ml reaction volume using Transcriptor First Strand cDNA
Synthesis kit (Roche Diagnostics, Mannheim, Germany). Random hexamer primers
were used for cDNA priming. One out of ten of the cDNA mixture was used in
PCR with Phusion High Fidelity DNA Polymerase (Finnzymes, Vantaa, Finland).
PCR conditions are published previously.6
qRT-PCR. qPCR reactions were performed in triplicates using LightCycler
detection system LC480 (Roche Diagnostics). Shortly, 5ml of 1 : 10 diluted cDNA
was used as a template in a mixture of specific pair of primers and LightCycler 480
SYBR Green I Master kit (Roche). The amplification cycle was repeated 45 times
with all samples as follow: 95 1C for 10 s with temperature transition rate 4.4 1C/s,
60 1C for 15 s with temperature transition rate 2.2 1C/s and 72 1C for 20 s with
temperature transition rate 4.4 1C/s. The changes in the mRNA levels following the
treatments were analyzed by relative expression software tool REST.12 The MIQE
guidelines39 were followed in assay design and analysis. The levels of the reference
transcripts did not change significantly by CHX treatment, as validated by the 2CT
method,40 P-values were calculated by Student’s t-test: fold change of treated
samples compared with DMSO-treated samples was 1.2 for ENO2 (P¼ 0.6), 1.5 for
NEFM (P¼ 0.5) and 1.1 for Actb (P¼ 0.4). As expected, ActD treatment did not
change the levels of RNA polymerase III-transcribed reference genes, calculated at
8 h treatment: fold change of treated samples compared with non-treated samples
for 7SLRNA was 0.95 (P¼ 0.4) in the cortical neurons and 0.92 (P¼ 0.4) in the
PC6 cells. For Rn18s: 0.7 (P¼ 0.3) in the cortical neurons and 0.93 (P¼ 0.3) in the
PC6 cells.
Immunoblots. Brain and liver samples for immunoblotting were homogenized
in the extraction buffer containing 0.3 M sucrose, 10 mM Hepes, pH 7.2, 1 mM
EDTA and EDTA-free protease inhibitor cocktail (CompleteMini, Roche) and then
5 Laemmli sample buffer was added. Cultured cells were lysed in 2.5 SDS
sample buffer (160ml/35 mm-dish). Samples were analyzed by SDS-PAGE in the
15% gels, blotted to nitrocellulose membranes and blocked with 5% non-fat dry
milk in TBS containing 0.1% Tween-20 (TBST). Membranes were probed with
the anti-Bak antibodies from EMD Millipore (06-536), Sigma (B-5897), Santa Cruz
Biotechnology, Inc., (G-23, sc-832), or Ab-2 (TC-102) (EMD Millipore, AM04).
Other antibodies were anti-Hsp70 from Stressgen Biotechnologies, Victoria, BC,
Canada (SPA810), anti-b-actin (Sigma) and anti-a-tubulin (Sigma). The blots were
then probed with the secondary antibodies: goat anti-mouse from DAKO (Golstrup,
Dennmark) or donkey anti-rabbit from GE Healthcare (Buckinghamshire, UK).
Immunoblots were developed using SuperSignal West Pico Chemiluminecent
Substrate (Pierce Biotechnology, Rockford, IL, USA) and Fujifilm LAS3000 imager
(Fuji Photo Film, Tokyo, Japan). For re-probing the filters were stripped with
washing buffer: 62.5 mM Tris-HCl, pH 6.8 containing 2% SDS and 100 mM
2-mercaptoethanol for 15 min at þ 55 1C and washed further with PBS and TBST.
Biochemical methods. In vitro translation was performed in the rabbit
reticulocyte lysate using TnT Quick Coupled Transcription/Translation System
(Promega) in the presence of 35S-methionine (Perkin-Elmer, Waltham, MA, USA)
according to the manufacturer’s instructions. HeLa cells were transfected by
Lipofectamine 2000 (Invitrogen). Blockage of translation by CHX was optimized by
metabolic labeling of SCG neurons followed by precipitation of the proteins by
trichloro-acetic acid and measuring the radioactivity by scintillation beta-counter.
Treatment with 20mg/ml of CHX for 4 h blocked 90–95% of new protein translation.
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